In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Strategy Business Strategies

Pharmaceutical Strategic Alliances: Sharing and Optimizing Risk

Executive Summary

If there was an overriding theme at this year's PSA, it was the search for balance of risk in pharma-biotech collaborations. PSA also showcased Big Pharma's efforts to expand in large molecules, and its attempts to dilute risk internally, by adopting the strategic habits of biotech companies.
Table

View full table

Advertisement

Related Content

In Vivo
Bristol Revs Its R&D Engine: An Interview with Elliott Sigal and Francis Cuss
In Vivo
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
In Vivo
Restructuring Roche's R&D: An Interview with Lee Babiss
In Vivo
Restructuring Roche's R&D: An Interview with Lee Babiss
In Vivo
Lilly's Chorus Experiment
In Vivo
Reviewing Five Years of Big Pharma's Biotech Acquisitions
In Vivo
Pfizer Deal Highlights Bristol's Biotech Swagger
In Vivo
Lilly's Chorus Experiment
In Vivo
Pfizer Deal Highlights Bristol's Biotech Swagger
In Vivo
Reviewing Five Years of Big Pharma's Biotech Acquisitions

Topics

Related Companies

Related Deals

Advertisement
Tags:
BioPharmaceutical Strategy Business Strategies
UsernamePublicRestriction

Register

IV003010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By